TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Skin Perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants in Amenorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Induction of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in loss of residual kidney function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Balance via Center of Pressure (COP) displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of gallstones formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean of Per Subject Percentages of Target Lesions Judged to be Clear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to clinical worsening
Endpoint domain: Mortality/survival
Primary endpoint: Change in Global Circumferential Strain (GCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Wound Re-epithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement of mineral metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Remission of secondary hyperparathyroidism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Expiratory peak flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in Relationship of Biomarker Alpha-fetoprotein (AFP) to Overall Survival (OS)
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Relationship of Biomarker Transforming Growth Factor - Beta (TGF-β) to Overall Survival (OS)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Grade 3 or Higher Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With ≥ 1 Adverse Event (AE) Leading to Treatment Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Insertion Time of device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in EAT amount
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: high-sensitive Troponin T
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Leukemia-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Estimation of tumor size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total grams of snack foods consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain Intensity change from Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient treatment compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Genitourinary Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Blood lactate Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Disease Control Rate at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Unprotected Acts of Intercourse
Endpoint domain: Adverse events/effects
Primary endpoint: clinical assessments of cosmetic outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: liver allograft survival
Endpoint domain: Mortality/survival
Primary endpoint: Fahn-Tolusa-Marsden Tremor Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: change in percent predicted FVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: resting arterial blood gas assessment of alveolar-arterial oxygen gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: percent predicted DLCO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tumor dimension and proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ki67 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tumor gene expression profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Stress sub-scale of DASS-21
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: MTD of tipifarnib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Removal Rate of Urea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Removal Rate of Creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Removal Rate of Albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Globotriaosylceramide (GL-3) Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Timely referral to genetic counseling
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of failure of spontaneous breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maternal redox homeostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal inflammatory profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal metabolic profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: duration of total virtual planning time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Capillary blood glucose levels (AUCbaseline_c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Experiencing ACR Pediatric 30 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolonged Abstinence Through 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median 3-year Recurrence-free Survival (RFS)
Endpoint domain: Mortality/survival
Primary endpoint: Solicited systemic and local reactogenicity signs and symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of adverse events of all severities
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of serious adverse events and new chronic medical conditions
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Specificity of HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in oxygenated hemoglobin at the prefrontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: IVF success
Endpoint domain: Mortality/survival
Primary endpoint: Postoperative Refractive Cylinder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Affective Theory of Mind
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cognitive Theory of Mind
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With Remission at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in Clinical Disease Activity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients reporting a decision for immediate antibiotics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Duration of diarrhoea before admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stool volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dehydration status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sallis Self Efficacy for Healthy Eating Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sallis Self Efficacy for Physical Activity Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PRX-105 plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hours Per Day of Fuss/Cry
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hours Per Day of Sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Maximum tolerated doses (MTDs)
Endpoint domain: Adverse events/effects
Primary endpoint: hemoglobin content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: expression of TET1 gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Categorical Visualization Score (CVS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Number of Lesions Detected in Pre-contrast and Combined Pre-/Post-contrast MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast to Noise Ratio (CNR) Between White and Gray Matter With Gadobutrol Perfusion MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Kevetrin
Endpoint domain: Adverse events/effects
Primary endpoint: Dose Limiting Toxicities (DLT) of Kevetrin
Endpoint domain: Adverse events/effects
Primary endpoint: clotting score of dialyser
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: occurrence of major and minor clotting events
Endpoint domain: Adverse events/effects
Primary endpoint: instantaneous blood clearances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Population pharmacokinetic model performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence/Absence of superficial surgical site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Log-Transformed Testicular Volume at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Anti-Corifollitropin Alfa Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short-term Exclusive Breastfeeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Long-term Exclusive Breastfeeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Safety and tolerability of the drug
Endpoint domain: Adverse events/effects
Primary endpoint: Simultaneous FFR measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Days to fistula closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: average ratio of hospital stays
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: average ratio of ambulatory acts
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Villous Height/Crypt Depth ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in serum IgA class anti-transglutaminase antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Arterial wall thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clearance of specific waste products from blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in AD specific component score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprotection Based on Toxin Neutralization Antibody Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of death from any cause
Endpoint domain: Mortality/survival
Primary endpoint: Emergence hypertension response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum levels of C3, C4 & C5a
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Drug Related Treatment-Emergent Adverse Events (TEAEs) or Serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Fetal intracardiac/ductal shunting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fetal pulmonary blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: BMI at the 95th percentile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IOP at the final visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: preference for tegaserod compared to PEG 3350
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment Success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epiglottis-to-vocal-cord distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Effective Sound Pressure Level (MEPO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peri-implant Soft Tissue Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DUS-detected recanalization rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: occurrence of PTS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of the number of caries, fillings and teeth missing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of oral hygiene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of temporo mandibular dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessing of mouth dryness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity of dengue NS1 Ag tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients who improve, worsen or do not present changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Sitting Systolic Blood Pressure (MSSBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Asthma Control Test (ACT)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Parkinsonian disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Upper-Respiratory Tract Infections (URTI) episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in average daily pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of prolongation of pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Dynamic Balance Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Tidal Variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change From Baseline to Week 12 in Inflammatory Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Absolute Change From Baseline to Week 12 in Non-inflammatory Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: self-reported adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Arabic Numeric Pain Rating Scale (ANPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arabic version of the reduced WOMAC index (ArWOMAC)- Function sub-scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Muscular symptom intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mechanical Alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of BNP in determining Heart Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 18F-Flutemetamol uptake in carotids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Plasma Concentration of Albuterol or Epinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) of Total Active Product Ingredient (API)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) of Exogenous Active Product Ingredient (API)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) of Albuterol or Epinephrine From Time 0 to Infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle strength scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of procedures conducted without complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in left ventricle diastolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of major or minor bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the number of thromboembolic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Seroconverted Subjects Against Human Rotavirus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in E to A Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial Glucose Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of regional ventilation partition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tinetti test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory sinus arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Image Guidance Adequacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline PERMA-Profiler score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Allodynia/hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pathogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Communication and satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Crown failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Frequency of clinically significant laboratory abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of clinically significant vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of clinically significant ECGs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarkers for vascular integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Biomarkers for inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CB1 density of brown adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute bone scan quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: in-hospital mortality of invasive candidas infection
Endpoint domain: Mortality/survival
Primary endpoint: change in lean body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Steady-State Concentration (Css) of Norelgestromin (NGMN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Steady-State Concentration (Css) of Ethinyl Estradiol (EE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve from Time 0 (Patch Application) to Infinite Time (AUC[0-infinity]) for NGMN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time 0 (Patch Application) to Infinite Time (AUC[0-infinity]) for EE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body's response to transcranial magnetic stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes